RONAPREVE

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Japan, Lithuania, New Zealand, Poland, Romania, United Kingdom

Active ingredients

The drug RONAPREVE contains a combination of these active pharmaceutical ingredients (APIs):

1 Casirivimab UNII J0FI6WE1QN - CASIRIVIMAB

2 Imdevimab UNII 2Z3DQD2JHM - IMDEVIMAB

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RONAPREVE Solution for injection/infusion	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BD07		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1864997, 1865055
Country: FR	Base de données publique des médicaments	Identifier(s): 64086026, 67613850
Country: IT	Agenzia del Farmaco	Identifier(s): 049766013, 049766025
Country: JP	医薬品医療機器総合機構	Identifier(s): 62505A0A1031, 62505A0A2038
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093629, 1093630
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 22691
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100459990
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68264001, W68265001